Trial Profile
A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Lopinavir/ritonavir (Primary) ; Stavudine (Primary) ; Zidovudine (Primary) ; Efavirenz; Lamivudine; Nevirapine
- Indications HIV infections; Malaria
- Focus Therapeutic Use
- Acronyms PROMOTE-pediatrics; PROMOTE-PEDS
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 30 Aug 2016 Results published in the Pediatric Infectious Disease Journal
- 08 Dec 2013 Results published in the JAIDS.